• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

February 15, 2021
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
Eli Lilly

Junshi Biosciences
bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) mild-to-moderate COVID-19 in patients age 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization Emergency Use Authorization (EUA) granted by the FDA
GenScript USA cPass SARS-CoV-2 Neutralization Antibody Detection Kit in convalescent plasma screening detection of COVID-19 neutralizing antibodies without the use of live virus EUA granted by the FDA
Other Trials and Actions
Adaptive Phage Therapeutics PhageBank therapy prosthetic joint infections IND approved by the FDA
Catapult Therapeutics CAP-100 hematological malignancies IND approved by the FDA
Ideaya Biosciences IDE397 solid tumors harboring MTAP deletion IND approved by the FDA
ImmunoMet Therapeutics IM156 idiopathic pulmonary fibrosis IND approved by the FDA
Intrommune Therapeutics INT301, oral mucosal immunotherapy peanut allergies IND approved by the FDA
NeurMedix NE3107 mild-to-moderate Alzheimer’s disease IND approved by the FDA for phase 3 trial
Passage Bio PBKR03 early infantile Krabbe disease (globoid cell leukodystrophy) IND approved by the FDA
Triastek T19 3D printed formulation rheumatoid arthritis IND approved by the FDA
I-Mab

Morphosys
TJ210/MOR210 advanced solid tumors IND approved by the China National Medical Products Administration
Celon Pharma CPL’116 autoimmune diseases completion of phase 1a trial
Cue Biopharma CUE-101 in combination with Keytruda (pembrolizumab) first-line treatment for HPV+ recurrent/metastatic head and neck squamous-cell carcinoma first patient dosed in phase 1 trial
Curis CA-4948 in combination with ibrutinib relapsed or refractory hematologic malignancies first patient dosed in phase 1 trial
Melt Pharmaceuticals Melt technology (midazolam 3 mg/ketamine 25 mg and midazolam 6 mg/ketamine 50 mg) sedation and analgesia for patients undergoing cataract surgery completion of phase 1 trial
Tessa Therapeutics TT11X – allogeneic CD30-CAR Epstein Barr virus-specific T-cell therapy CD30+ lymphoma completion of dosing in first patient cohort in phase 1 trial
Regulus Therapeutics RGLS4326 autosomal dominant polycystic kidney disease completion of patient enrollment in first cohort of phase 1b trial
Vaccitech VTP-300 with and without a low-dose anti-PD-1 antibody chronic hepatitis B infection first patient dosed in phase 1b/2a trial
Gemini Therapeutics GEM103 dry age-related macular degeneration with complement factor H (CFH) and loss-of-function gene variants completion of patient enrollment in phase 2a trial
Brooklyn Immunotherapeutics IRX-2 in combination with pembrolizumab (Keytruda) and chemotherapy triple-negative breast cancer initiation of phase 2 trial
Trefoil Therapeutics TTHX1114 Fuchs endothelial corneal dystrophy initiation of phase 2 trial
Navidea Biopharmaceuticals NAV3-32 rheumatoid arthritis initiation of phase 2b trial
Evolve Biologic PlasmaCap IG (intravenous immunoglobulin) adults and children with primary immune deficiency disease completion of phase 3 trial
Innovent Biologics IBI310 in combination with Tyvyt (sintilimab) injection first-line treatment of advanced hepatocellular carcinoma first patient dosed in phase 3 trial
ImmunoMet Therapeutics IM156 idiopathic pulmonary fibrosis Orphan Drug designation granted by the FDA
Vascular Perfusion Solutions VP.S Encore oxygenated perfusion cardiac transport device preservation of vascularized tissue Breakthrough Device designation granted by the FDA
Puzzle Medical Devices minimally invasive transcatheter heart pump heart failure Breakthrough Device designation granted by the FDA
Allergan Botox (onabotulinumtoxinA) detrusor overactivity associated with a neurologic condition in patients age five and older who have an inadequate response to or are intolerant of anticholinergic medication approved by the FDA for additional indication
Bristol Myers Squibb/Juno Therapeutics Breyanzi (lisocabtagene maraleucel) patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment approved by the FDA
Regeneron

Sanofi
Libtayo (cemiplimab-rwlc) locally advanced and metastatic basal cell carcinoma approved by the FDA
Rhizen Pharmaceuticals

TG Therapeutics
Ukoniq (umbralisib) relapsed or refractory marginal-zone lymphoma and follicular lymphoma accelerated approval granted by the FDA
Signifier Medical Technologies eXciteOSA daytime intraoral neuromuscular stimulation device mild obstructive sleep apnea and snoring approved by the FDA

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing